@article{d97720defec940ebaf957e43f18974ba,
title = "Clinical and cortical decline in the aphasic variant of Alzheimer's disease",
abstract = " Introduction: Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation. Methods: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid PET (PPA Aβ+ and PPA Aβ− ), an imaging biomarker of underlying Alzheimer's disease. Results: Over 12 months, both PPA groups showed significantly greater cortical atrophy rates in the left versus right hemisphere, with a more widespread pattern in PPA Aβ+ . The PPA Aβ+ group also showed greater decline in performance on most language tasks. There was no obligatory relationship between the logopenic PPA variant and amyloid status. Effect sizes from quantitative MRI data were more robust than neuropsychological metrics. Discussion: Preferential language network neurodegeneration is present in PPA irrespective of amyloid status. Clinical and anatomical progression appears to differ for PPA due to Alzheimer's disease versus non–Alzheimer's disease neuropathology, a distinction that may help to inform prognosis and the design of intervention trials. ",
keywords = "Amyloid PET, Biomarker, FreeSurfer, Frontotemporal dementia, Frontotemporal lobar degeneration, Neuropsychology, Primary progressive aphasia, Progression, Volumetric MRI",
author = "Rogalski, {Emily Joy} and Jaiashre Sridhar and Adam Martersteck and Benjamin Rader and Derin Cobia and Arora, {Anupa K.} and Fought, {Angela J.} and Bigio, {Eileen H.} and Sandra Weintraub and Mesulam, {Marek Marsel} and Alfred Rademaker",
note = "Funding Information: Study Funding: This project was supported in part by DC008552 from the National Institute on Deafness and Communication Disorders ; AG13854 (Alzheimer Disease Core Center) and AG056258 from the National Institute on Aging ; and NS075075 from the National Institute of Neurological Disorders and Stroke (NINDS). Funding Information: A.M., B.R., J.S., A.J.F., and A.R. have nothing to disclose. Drs. Bigio, Weintraub, Cobia, Mesulam, and Rogalski report grants from NIH during the conduct of the study. 18F-florbetapir doses were provided as nonfinancial support by Avid Radiopharmaceuticals (awarded to E.R.). Dr. Arora is an employee of Avid Radiopharmaceuticals.Study Funding: This project was supported in part by DC008552 from the National Institute on Deafness and Communication Disorders; AG13854 (Alzheimer Disease Core Center) and AG056258 from the National Institute on Aging; and NS075075 from the National Institute of Neurological Disorders and Stroke (NINDS). Funding Information: A.M., B.R., J.S., A.J.F., and A.R. have nothing to disclose. Drs. Bigio, Weintraub, Cobia, Mesulam, and Rogalski report grants from NIH during the conduct of the study. 18F-florbetapir doses were provided as nonfinancial support by Avid Radiopharmaceuticals (awarded to E.R.). Dr. Arora is an employee of Avid Radiopharmaceuticals.The authors thank Christina Coventry, Emmaleigh Loyer, Marie Saxon, Amanda Rezutek, Maureen Connelly, Danielle Barkema, and Kristen Whitney for neuropsychological test administration of the participants and Allison Rainford for her assistance with FreeSurfer MR processing. MR Imaging was performed at the Northwestern University Department of Radiology Center for Translational Imaging (CTI). PET Imaging was performed at Northwestern Memorial Hospital. The authors thank Avid Radiopharmaceuticals for the amyloid PET doses for this study. Study Funding: This project was supported in part by DC008552 from the National Institute on Deafness and Communication Disorders; AG13854 (Alzheimer Disease Core Center) and AG056258 from the National Institute on Aging; and NS075075 from the National Institute of Neurological Disorders and Stroke (NINDS). Authors' contributions: M.M.M. E.J.R. S.W. and A.R. contributed to the concept and design of the study. M.M.M. E.R. S.W. and B.R. contributed to data acquisition. All authors contributed to data analysis and interpretation and provided critical revision of the manuscript for important intellectual content. Study supervision was done by E.R. B.R. and J.S. Statistical Analyses were completed by A.R and A.F. Publisher Copyright: {\textcopyright} 2019 the Alzheimer's Association Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = apr,
doi = "10.1016/j.jalz.2018.12.003",
language = "English (US)",
volume = "15",
pages = "543--552",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",
}
